Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that Genedata Screener® for Ion Channel Screening will be a featured presentation at the 10th Annual Ion Channel Retreat. The Retreat showcases new screening technologies and the importance of improving the safety of target compounds. The Genedata presentation will show how to overcome current issues in Ion Channel data analysis on real-life examples using Genedata Screener for Ion Channel Screening.
The new Genedata Screener for Ion Channel Screening is a first-in-class Ion Channel screening solution that enables scalable and automated data analysis. The software’s exceptional data loading and processing speed combined with the ability to simultaneously process multiple plates significantly reduces analysis time. Part of the Retreat’s Ion Channel Screening session, the Genedata presentation will highlight analyses of two distinct datasets from leading pharmaceutical companies that collaborate with Genedata.
Today’s electrophysiology experiments measure simultaneously 1000s of compounds and 100,000s of data points per day, producing gigabytes of raw data – for which the data analysis renders a severe bottleneck. Genedata Screener’s streamlined data analysis workflows for microfluidics-based Automated Patch Clamp (APC) experiments increase the sample throughput and the level of detail in biological characterizations. The Genedata session will present a case study that:
• Overviews typical challenges in APC data analysis
• Discusses specific problems in uncovering relevant biological effects
• Demonstrates single- and multi-compound workflows that mitigate data analysis risks
• Provides examples on how analysis time can be reduced and result quality improved with automated analysis workflows
Genedata Screener for Ion Channel Screening easily integrates into corporate screening data analysis environments, and imports data from various well/plate instruments including Fluxion Ionflux™ and MD IonWorks® Quattro™ and Barracuda™.
“With the latest innovations in miniaturization and automation, screening instrumentation now enables parallel testing applying innovative technologies such as APC, which results in data of unprecedented volume, complexity, and value,” said Dr. Othmar Pfannes, CEO of Genedata. “With Genedata Screener for Ion Channel Screening, we enable scientists to take advantage of these technologies by empowering them to efficiently analyze and interpret this data. Our support of Automated Electrophysiology underscores the Genedata commitment to advanced screening technologies such as High Content and Label-Free screening.”
NOTE: The Genedata session --“High-volume data analysis workflows for microfluidics-based automated patch clamps” -- will be presented by Dr. Stephan Steigele on June 27 at 3:00pm EDT. To schedule a briefing email: firstname.lastname@example.org.
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery, industrial biotechnology, and life science research. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata solutions make research data accessible and understandable, enabling scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Japan, Germany, and the US. www.genedata.com
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.